Cargando…

Clinical outcomes of surgical management for rare types of progressive familial intrahepatic cholestasis: a case series

BACKGROUND: Progressive familial intrahepatic cholestasis (PFIC) is a heterogeneous group of genetic autosomal recessive diseases that cause severe cholestasis, which progresses to cirrhosis and liver failure, in infancy or early childhood. We herein report the clinical outcomes of surgical manageme...

Descripción completa

Detalles Bibliográficos
Autores principales: Masahata, Kazunori, Ueno, Takehisa, Bessho, Kazuhiko, Kodama, Tasuku, Tsukada, Ryo, Saka, Ryuta, Tazuke, Yuko, Miyagawa, Shuji, Okuyama, Hiroomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758805/
https://www.ncbi.nlm.nih.gov/pubmed/35024979
http://dx.doi.org/10.1186/s40792-022-01365-1
_version_ 1784632993926610944
author Masahata, Kazunori
Ueno, Takehisa
Bessho, Kazuhiko
Kodama, Tasuku
Tsukada, Ryo
Saka, Ryuta
Tazuke, Yuko
Miyagawa, Shuji
Okuyama, Hiroomi
author_facet Masahata, Kazunori
Ueno, Takehisa
Bessho, Kazuhiko
Kodama, Tasuku
Tsukada, Ryo
Saka, Ryuta
Tazuke, Yuko
Miyagawa, Shuji
Okuyama, Hiroomi
author_sort Masahata, Kazunori
collection PubMed
description BACKGROUND: Progressive familial intrahepatic cholestasis (PFIC) is a heterogeneous group of genetic autosomal recessive diseases that cause severe cholestasis, which progresses to cirrhosis and liver failure, in infancy or early childhood. We herein report the clinical outcomes of surgical management in patients with four types of PFIC. CASE PRESENTATION: Six patients diagnosed with PFIC who underwent surgical treatment between 1998 and 2020 at our institution were retrospectively assessed. Living-donor liver transplantation (LDLT) was performed in 5 patients with PFIC. The median age at LDLT was 4.8 (range: 1.9–11.4) years. One patient each with familial intrahepatic cholestasis 1 (FIC1) deficiency and bile salt export pump (BSEP) deficiency died after LDLT, and the four remaining patients, one each with deficiency of FIC1, BSEP, multidrug resistance protein 3 (MDR3), and tight junction protein 2 (TJP2), survived. One FIC1 deficiency recipient underwent LDLT secondary to deterioration of liver function, following infectious enteritis. Although he underwent LDLT accompanied by total external biliary diversion, the patient died because of PFIC-related complications. The other patient with FIC1 deficiency had intractable pruritus and underwent partial internal biliary diversion (PIBD) at 9.8 years of age, pruritus largely resolved after PIBD. One BSEP deficiency recipient, who had severe graft damage, experienced recurrence of cholestasis due to the development of antibodies against BSEP after LDLT, and eventually died due to graft failure. The other patient with BSEP deficiency recovered well after LDLT and there was no evidence of posttransplant recurrence of cholestasis. In contrast, recipients with MDR3 or TJP2 deficiency showed good courses and outcomes after LDLT. CONCLUSIONS: Although LDLT was considered an effective treatment for PFIC, the clinical courses and outcomes after LDLT were still inadequate in patients with FIC1 and BSEP deficiency. LDLT accompanied by total biliary diversion may not be as effective for patients with FIC1 deficiency.
format Online
Article
Text
id pubmed-8758805
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-87588052022-01-20 Clinical outcomes of surgical management for rare types of progressive familial intrahepatic cholestasis: a case series Masahata, Kazunori Ueno, Takehisa Bessho, Kazuhiko Kodama, Tasuku Tsukada, Ryo Saka, Ryuta Tazuke, Yuko Miyagawa, Shuji Okuyama, Hiroomi Surg Case Rep Case Report BACKGROUND: Progressive familial intrahepatic cholestasis (PFIC) is a heterogeneous group of genetic autosomal recessive diseases that cause severe cholestasis, which progresses to cirrhosis and liver failure, in infancy or early childhood. We herein report the clinical outcomes of surgical management in patients with four types of PFIC. CASE PRESENTATION: Six patients diagnosed with PFIC who underwent surgical treatment between 1998 and 2020 at our institution were retrospectively assessed. Living-donor liver transplantation (LDLT) was performed in 5 patients with PFIC. The median age at LDLT was 4.8 (range: 1.9–11.4) years. One patient each with familial intrahepatic cholestasis 1 (FIC1) deficiency and bile salt export pump (BSEP) deficiency died after LDLT, and the four remaining patients, one each with deficiency of FIC1, BSEP, multidrug resistance protein 3 (MDR3), and tight junction protein 2 (TJP2), survived. One FIC1 deficiency recipient underwent LDLT secondary to deterioration of liver function, following infectious enteritis. Although he underwent LDLT accompanied by total external biliary diversion, the patient died because of PFIC-related complications. The other patient with FIC1 deficiency had intractable pruritus and underwent partial internal biliary diversion (PIBD) at 9.8 years of age, pruritus largely resolved after PIBD. One BSEP deficiency recipient, who had severe graft damage, experienced recurrence of cholestasis due to the development of antibodies against BSEP after LDLT, and eventually died due to graft failure. The other patient with BSEP deficiency recovered well after LDLT and there was no evidence of posttransplant recurrence of cholestasis. In contrast, recipients with MDR3 or TJP2 deficiency showed good courses and outcomes after LDLT. CONCLUSIONS: Although LDLT was considered an effective treatment for PFIC, the clinical courses and outcomes after LDLT were still inadequate in patients with FIC1 and BSEP deficiency. LDLT accompanied by total biliary diversion may not be as effective for patients with FIC1 deficiency. Springer Berlin Heidelberg 2022-01-13 /pmc/articles/PMC8758805/ /pubmed/35024979 http://dx.doi.org/10.1186/s40792-022-01365-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Case Report
Masahata, Kazunori
Ueno, Takehisa
Bessho, Kazuhiko
Kodama, Tasuku
Tsukada, Ryo
Saka, Ryuta
Tazuke, Yuko
Miyagawa, Shuji
Okuyama, Hiroomi
Clinical outcomes of surgical management for rare types of progressive familial intrahepatic cholestasis: a case series
title Clinical outcomes of surgical management for rare types of progressive familial intrahepatic cholestasis: a case series
title_full Clinical outcomes of surgical management for rare types of progressive familial intrahepatic cholestasis: a case series
title_fullStr Clinical outcomes of surgical management for rare types of progressive familial intrahepatic cholestasis: a case series
title_full_unstemmed Clinical outcomes of surgical management for rare types of progressive familial intrahepatic cholestasis: a case series
title_short Clinical outcomes of surgical management for rare types of progressive familial intrahepatic cholestasis: a case series
title_sort clinical outcomes of surgical management for rare types of progressive familial intrahepatic cholestasis: a case series
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758805/
https://www.ncbi.nlm.nih.gov/pubmed/35024979
http://dx.doi.org/10.1186/s40792-022-01365-1
work_keys_str_mv AT masahatakazunori clinicaloutcomesofsurgicalmanagementforraretypesofprogressivefamilialintrahepaticcholestasisacaseseries
AT uenotakehisa clinicaloutcomesofsurgicalmanagementforraretypesofprogressivefamilialintrahepaticcholestasisacaseseries
AT besshokazuhiko clinicaloutcomesofsurgicalmanagementforraretypesofprogressivefamilialintrahepaticcholestasisacaseseries
AT kodamatasuku clinicaloutcomesofsurgicalmanagementforraretypesofprogressivefamilialintrahepaticcholestasisacaseseries
AT tsukadaryo clinicaloutcomesofsurgicalmanagementforraretypesofprogressivefamilialintrahepaticcholestasisacaseseries
AT sakaryuta clinicaloutcomesofsurgicalmanagementforraretypesofprogressivefamilialintrahepaticcholestasisacaseseries
AT tazukeyuko clinicaloutcomesofsurgicalmanagementforraretypesofprogressivefamilialintrahepaticcholestasisacaseseries
AT miyagawashuji clinicaloutcomesofsurgicalmanagementforraretypesofprogressivefamilialintrahepaticcholestasisacaseseries
AT okuyamahiroomi clinicaloutcomesofsurgicalmanagementforraretypesofprogressivefamilialintrahepaticcholestasisacaseseries